Company news

Telix Pharmaceuticals Limited news in 2026

Telix Pharmaceuticals Limited's news releases, calls and decks from 2026, newest first.

View company

Appendix 3Y Maria Rivas

November 4, 2026

Telix Capital Markets Day Presentation November 2026

November 3, 2026

Change of Director's Interest Notice - Marie McDonald

November 3, 2026

Notification regarding unquoted securities - TLX

November 3, 2026

Cancellation of Appendix 2A

November 2, 2026

Notice of General Meeting

October 29, 2026

Telix Notice of General Meeting, Proxy Form and Online Guide

October 29, 2026

Application for quotation of securities - TLX

October 28, 2026

Appendix 3Y Dr Christian Behrenbruch

October 26, 2026

Appendix 3Y William Jellison

October 25, 2026

Appendix 3Y Change in Director Interest - D Gill

October 25, 2026

Telix Reports Third Quarter 2026 Financial Performance

October 20, 2026

Telix Reports Third Quarter 2026 Financial Performance

October 20, 2026

Telix Highlights Pivotal Trials in Prostate, Brain and Renal Cancers and Next Generation Theranostics at EANM

October 14, 2026

Telix to Host Capital Markets Day in Melbourne on November 4, 2026

October 8, 2026

First Patients Dosed with Telix’s FDA-Approved Brain Cancer Imaging Drug Pixclara (floretyrosine F 18)

October 6, 2026

First Patients Dosed with Telix’s FDA-Approved Brain Cancer Imaging Drug Pixclara® (floretyrosine F 18)

October 6, 2026

Notification of cessation of securities - TLX

October 4, 2026

Notification of cessation of securities - TLX

October 4, 2026

Notification regarding unquoted securities - TLX

October 4, 2026

Application for quotation of securities - TLX

October 4, 2026

Telix Granted FDA Fast Track Designation for BiPASS Pre-Biopsy Prostate Cancer Imaging

September 29, 2026

FDA Fast Track for BiPASS Pre Biopsy Prostate Imaging

September 29, 2026

Change in substantial holding

September 25, 2026

Appendix 3Y Change in Director Interest-D Gill

September 25, 2026

Application for quotation of securities - TLX

September 25, 2026

Grant of waivers of Listing Rule 7.3.4

September 21, 2026

Telix and ITM Join Forces to Create a Radiopharmaceutical Powerhouse

September 20, 2026

Telix and ITM Join Forces to Create Radiopharma Powerhouse

September 20, 2026

Telix and ITM Join Forces to Create Radiopharma Powerhouse

September 20, 2026

Telix and ITM Join Forces to Create Radiopharma Powerhouse

September 20, 2026

FDA Approves Telix's Brain Cancer Imaging Drug Pixclara

September 13, 2026

Application for quotation of securities - TLX

September 14, 2026

FDA Approves Telix Brain Cancer Imaging Drug Pixclara

September 13, 2026

Telix to Present at the Morgan Stanley 24th Annual Global Healthcare Conference and H.C. Wainwright 28th Annual Global Investment Conference

September 9, 2026

Telix Completes Enrollment in Phase 3 BiPASS Study, Aligns with FDA on NDA Pathway

September 1, 2026

Telix Completes Enrollment in Phase 3 BiPASS Study

September 1, 2026

Telix Appoints David Gill as Chair

August 31, 2026

Telix 2026 Half-Year Results: Strong Commercial Execution and Momentum in Late-Stage Pipeline

August 19, 2026

Telix HY26 Results Presentation

August 19, 2026

Telix HY26 Results Announcement

August 19, 2026

Telix HY26 Appendix 4D and Interim Report

August 19, 2026

Telix to Host R&D Day in New York City on September 22, 2026

August 5, 2026

Telix H1 2026 Results: Investor Webcast Notification

July 30, 2026

Telix H1 2026 Results - Investor Webcast Notification

July 30, 2026

TLX591-Tx ProstACT SELECT Study Published in Cancers Journal

July 21, 2026

Telix Q2 Revenue US$247M, Strong Momentum and Pipeline Progress

July 20, 2026

Q2 2026 Revenue US$247M Strong Momentum Pipeline Progress

July 20, 2026

Telix Doses First Patient in Phase 3 LUTEON Trial of TLX250-Tx for Renal Cancer

July 20, 2026

Telix Completes Patient Enrollment in TLX591-Px (Illuccix®) Japan Phase 3 Study

July 16, 2026

Older news releases →

Calls in 2026

Decks in 2026